Trial reportBone marrow transplantation2015
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.
Open access · bronzeAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis.Annals of hematology · 2021Pooled it
- Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma.Scientific reports · 2025Trial
- Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023Review
- Article
- [Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in mobilization of autologous peripheral hematopoietic stem cells in patients with newly diagnosed multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- High Efficacy of Stem Cell Mobilization With Etoposide+Cytarabine Plus G-CSF in Patients With Multiple Myeloma.Frontiers in oncology · 2022Article
- The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft.Bone marrow transplantation · 2021Article
- Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era.Transplantation and cellular therapy · 2021Article
- Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma.Bone marrow transplantation · 2020Observational
- Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost.Leukemia research reports · 2020Article
- Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.Bone marrow transplantation · 2019Review
- Neurological complications of hematopoietic cell transplantation in children and adults.Neural regeneration research · 2018Review
- Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.International journal of hematology · 2018Article
- Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?World journal of transplantation · 2017Review
- Mobilization of Hematopoietic Stem Cells for Hematopoietic Cells Autologous Transplantation with Use of Plerixafor.Annals of transplantation · 2017Article
- Mobilization policy in multiple myeloma: minimum target or law of redundancy? Two different approaches by the two sides of the Atlantic Ocean.Bone marrow transplantation · 2016Article
- Stem Cell Mobilization with G-CSF versus Cyclophosphamide plus G-CSF in Mexican Children.Stem cells international · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 20 institutions in 7 countries.
G L UyDepartment of Medicine, Washington University School of Medicine, St Louis, MO, USA.
L J CostaDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
P N HariCenter for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
M-J ZhangCenter for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
J-X HuangCenter for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
K C AndersonHematologic Oncology Treatment Center, Dana-Farber Cancer Institute, Boston, MA, USA.
C N BredesonThe Ottawa Hospital Blood and Marrow Transplant Program and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
N S CallanderUniversity of Wisconsin Carbone Cancer Center, Madison, WI, USA.
R F CornellDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
M A D PerezServicio de Oncohematologia, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.
A DispenzieriDepartment of Hematology, Mayo Clinic, Rochester, MN, USA.
C O FreytesSouth Texas Veterans Health Care System and University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
R P GaleHematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.
A GarfallDivision of Hematology/Oncology, Perelman Center for Advanced Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
M A GertzDepartment of Hematology, Mayo Clinic, Rochester, MN, USA.
J GibsonHaematology Department, Royal Prince Alfred Hospital Institute of Haematology, Camperdown, New South Wales, Australia.
M HamadaniCenter for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
H M LazarusSeidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.
M E KalaycioHematologic Oncology and Blood Disorders, Cleveland Clinic, Cleveland, OH, USA.
R T KambleDivision of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
M A Kharfan-DabajaDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
A Y KrishnanDepartment of Hematology/Oncology, City of Hope National Medical Center, Duarte, CA, USA.
S K KumarDepartment of Hematology, Mayo Clinic, Rochester, MN, USA.
R A KyleDepartment of Hematology, Mayo Clinic, Rochester, MN, USA.
H J LandauBone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
C H LeeHaematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital/SA Pathology, Adelaide, South Australia, Australia.
A MaiolinoHospital Universitário Clementinio Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
D I MarksPediatric Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, UK.
T M MarkDepartment of Medicine, New York Presbyterian Hospital at Cornell, New York, NY, USA.
R MunkerSection of Hematology/Oncology, Department of Internal Medicine, Louisiana State University Health Shreveport, Shreveport, LA, USA.
T NishihoriDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
R F OlssonDivision of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
M RamanathanDivision of Hematology and Oncology, Department of Medicine, UMass Memorial Medical Center, Worcester, MA, USA.
T E RodriguezBone Marrow Transplant Program, Loyola University Medical Center, Chicago, IL, USA.
A A SaadDivision of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
B N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
G J SchillerBone Marrow Transplant Program, UCLA Center for Health Sciences, Los Angeles, CA, USA.
H C SchoutenDepartment of Hematology, Academische Ziekenhuis, Maastricht, The Netherlands.
J R SchriberCancer Transplant Institute, Virginia G. Piper Cancer Center, Scottsdale, AZ, USA.
E ScottCenter for Hematologic Malignancies, Oregon Health and Science University, Portland, OR, USA.
S SeoDepartment of Vaccine and Infectious Disease, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
M SharmaDepartment of Hematology/Oncology, Thomas Jefferson University, Philadelphia, PA, USA.
S GangulyBlood and Marrow Transplantation, Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, KS, USA.
E A StadtmauerDivision of Hematology/Oncology, Perelman Center for Advanced Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
J TayDepartment of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
L B ToHaematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital/SA Pathology, Adelaide, South Australia, Australia.
D H VesoleHackensack University Medical Center, Hackensack, NJ, USA.
D T VoglDivision of Hematology/Oncology, Perelman Center for Advanced Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
J L WagnerDepartment of Hematology/Oncology, Thomas Jefferson University, Philadelphia, PA, USA.
B WirkSeattle Cancer Care Alliance, Seattle, WA, USA.
W A WoodDivision of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
A D'SouzaCenter for International Blood and Marrow Transplant Research (CIBMTR), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Medical College of Wisconsin · USMayo Clinic in Arizona · USUniversity of Pennsylvania · USMoffitt Cancer Center · USSouth Australia Pathology · AUThomas Jefferson University · USUniversity of Alabama at Birmingham · USVanderbilt University Medical Center · USArizona Oncology · USBaylor College of Medicine · USCity Of Hope National Medical Center · USCleveland Clinic · USDana-Farber Cancer Institute · USFred Hutch Cancer Center · USHackensack University Medical Center · USHospital Infantil Universitario Niño Jesús · ESHospital Universitário Clementino Fraga Filho · BRImperial College London · GBKarolinska Institutet · SELouisiana State University · US
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3MData Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MEasy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8MProject 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5MClincal and Translational Science AwardUL1TR000055 · NCATS · MEDICAL COLLEGE OF WISCONSIN · PI SHAKER, REZA NONE · 2012 to 2015
$11.3MBone Marrow Transplant Clinical NetworkU10HL069286 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI STADTMAUER, EDWARD A · 2011 to 2016
$986kNCATS NIH HHS UL1 TR000055NCI NIH HHS P50 CA186781NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069286NHLBI NIH HHS U10 HL069294
Abstract
In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF (CC+GF). It is uncertain whether the method of mobilization affects post-transplant outcomes. We compared these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center for International Blood and Marrow Transplant Research database who received an auto-HCT in the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (⩾0.5 × 10(9)/L) was similar between groups (13 vs 13 days, P=0.69) while platelet engraftment (⩾20 × 10(9)/L) was slightly faster with CC+GF (19 vs 18 days, P=0.006). Adjusted 3-year PFS was 43% (95% confidence interval (CI) 38-48) in GF and 40% (95% CI 35-45) in CC+GF, P=0.33. Adjusted 3-year OS was 82% (95% CI 78-86) vs 80% (95% CI 75-84), P=0.43 and adjusted 5-year OS was 62% (95% CI 54-68) vs 60% (95% CI 52-67), P=0.76, for GF and CC+GF, respectively. We conclude that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of mobilization and found no evidence that the addition of chemotherapy to mobilization contributes to disease control.
Indexed as
Hematopoietic Stem Cell TransplantationAdolescentAdultAgedAutograftsDisease-Free SurvivalFemaleHematopoietic Stem Cell MobilizationHumansLeukocyte CountMaleMiddle AgedMultiple MyelomaPlatelet CountProspective StudiesRecovery of Function
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.